 AIM ImmunoTech Inc NYSEAMERICAN:AIM FRA:HXB2 has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited Smoore with the goal of developing Ampligen as a potential inhalation therapy for coronavirus COVID-19 and other respiratory viral diseases. In April 2020, AIM entered into the material transfer and research agreement to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic. 